US Edition
News from Clinical Trials Arena
If you want to know if Clinical Trials Arena is credible or reliable, look no further. We rank Clinical Trials Arena as Unknown factuality. Find out more about our methodology here.
Information about Clinical Trials Arena
Where is Clinical Trials Arena located?Clinical Trials Arena's WebsiteMedia Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Clinical Trials Arena News
GLP-1 · United StatesAscletis Pharma has dosed the first participants in a US Phase II trial of ASC30, an oral small molecule GLP-1 receptor agonist, intended for treating type 2 diabetes mellitus.The post Ascletis initiates participant dosing in Phase II trial of ASC30 for diabetes appeared first on Clinical Trials Arena.See the Story
Ascletis Initiates Participant Dosing in Phase II Trial of ASC30 for Diabetes
68% Center coverage: 22 sources
ObesityRoche Holdings AG (OTC:RHHBY) on Tuesday released topline results from the CT388-103 Phase 2 trial of CT-388 for obesity. CT-388 is an investigational once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed for the treatment of obesity, type 2 diabetes, and other obesity-related comorbidities. Trial Data The 469-patient trial was designed to evaluate the efficacy and safety of CT-388 at low, middle, and high doses. I…See the Story
Roche's Obesity Drug Helps Almost 87% People Lose At Least 10% Weight - Roche Holding (OTC:RHHBY)
67% Center coverage: 6 sources
